Glenmark Pharmaceuticals USA has launched Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg. The tablets, 12.5 mg, 25 mg, 50 mg and 100 mg is the authorised generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg.

Commenting on the launch, Marc Kikuchi, President and Business Head — North America, Glenmark, said, “We are excited to announce the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg, the authorised generic to Savella Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients.

According to IQVIA sales data for the 12-month period ending January 2026, the Savella Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg market achieved annual sales of approximately USD 102.9 million.